Cytogen, Inc. (217330.KQ)
- Previous Close
4,405.00 - Open
4,800.00 - Bid 4,025.00 x --
- Ask 4,040.00 x --
- Day's Range
3,765.00 - 4,800.00 - 52 Week Range
2,920.00 - 11,750.00 - Volume
1,668,698 - Avg. Volume
98,833 - Market Cap (intraday)
92.855B - Beta (5Y Monthly) -0.10
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Cytogen, Inc., a biotechnology company, engages in blood cancer cell-based Liquid Biopsy application business in South Korea. The company offers cell isolators that enrich CTCs from human blood and/or body fluid using high density microporous chips; IF stainers, automated immunofluorescent staining system; and cell image analyzers, which help captures immunofluorescent images of cells stained with anti-EpCAM, -CD45, and CK antibodies. The company sells its products under the Smart Biopsy brand name. Cytogen, Inc. was founded in 2010 and is headquartered in Seoul, South Korea.
www.cytogenlab.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: 217330.KQ
View MorePerformance Overview: 217330.KQ
Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 217330.KQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 217330.KQ
View MoreValuation Measures
Market Cap
92.85B
Enterprise Value
66.46B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
8.33
Price/Book (mrq)
1.91
Enterprise Value/Revenue
6.09
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-156.88%
Return on Assets (ttm)
-9.07%
Return on Equity (ttm)
-33.46%
Revenue (ttm)
10.91B
Net Income Avi to Common (ttm)
-17.12B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
41.27B
Total Debt/Equity (mrq)
30.38%
Levered Free Cash Flow (ttm)
-11.34B